Geneva, April 28 -- International Clinical Trials Registry received information related to the study (ChiCTR2600122474) titled 'A randomized phase II study: Evaluating the efficacy of innovative stereotactic body radiotherapy (SCART) versus conventional radiotherapy (CRT) in massive metastatic cancer' on April 14.
Study Type: Interventional study
Study Design:
Cross-sectional
Primary Sponsor: Foshan Fosun Chancheng Hospital
Condition:
Malignant tumor
Intervention:
SCART group:Innovative Stereotactic Body External Radiation Therapy Group: The dose level is 21Gy delivered in 3 fractions, while maintaining a margin dose of 5Gy per fraction around the entire tumor boundary. This is followed by two sequential precise radiation treatmen...